Proliareg; (denosumab) Arriving Worldwide for the treatment of postmenopausal osteoporosis — ...
Clicks: 316, website added: Jul 1, 2015
| ||||||||||||||||||
Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.